Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment

• Published in: International Journal of Methods in Psychiatric Research Vol. 23; no. 4; pp. 439 - 450
• Main Authors: Detke, Holland C., Lauriello, John, Landry, John, McDonnell, David P.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.12.2014; Wiley; John Wiley & Sons, Inc; John Wiley and Sons Inc
• Subjects: Adult; antipsychotic; Antipsychotic Agents; Antipsychotic Agents - therapeutic use; benefit-risk; Benzodiazepines; Benzodiazepines - therapeutic use; Delayed-Action Preparations; Drug Administration Schedule; Drug therapy; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; long-acting injection; Male; Middle Aged; Olanzapine; olanzapine pamoate; Psychiatric Status Rating Scales; Qualitative research; Risk Assessment; Schizophrenia; Schizophrenia - drug therapy; Time Factors; Treatment Outcome; antipsychotic; schizophrenia; olanzapine pamoate; long-acting injection; benefit-risk

We sought to evaluate the within‐drug benefit‐risk of olanzapine long‐acting injection (LAI) using both quantitative and qualitative methods. Subjects included 1192 adult patients with schizophrenia or schizoaffective disorder who participated in clinical trials with the opportunity for at least two...